Abstract 64P
Background
The burden of metastatic breast cancer (mBC) is high in many low-middle income countries. Given the wider social and economic implications associated with advanced cancer, understanding the unmet needs of patients with mBC is crucial towards the design and provision of tailored supportive care. We aimed to determine the unmet needs of women newly diagnosed with mBC in a middle-income Asian setting with limited cancer survivorship services.
Methods
Women who were diagnosed with mBC in the 12 months preceding the study were recruited from a Ministry of Health hospital, an academic hospital, and two private hospitals in Malaysia, an upper-middle income Asian country. Unmet needs were assessed using the Needs Assessment Tool for Breast Cancer (NeAT-BC), a 48-item dual language questionnaire that we had previously developed and validated in the local setting.
Results
In this interim analysis with 96 participants, 74% of women indicated having at least one unmet need. The highest unmet needs were reported for the hospital appointments domain (79.2%) as well as the information and services domain (80.2%). Besides the need for shorter waiting times in the hospital (88.5%), many women also described having unmet needs regarding information on daily aspects of living including on diet (79.2%) and self-care (78.1%). Finance-wise, 62.5% reported needing help to pay for their cancer therapies, while 59.4% expressed an unmet need for affordable transportation options to the hospital. In this setting with strong sociocultural beliefs on traditional and complementary therapies (TCM), 53.1% of women with mBC reported an unmet need for open discussions with their healthcare providers on the use of TCM. No significant differences in the overall level of unmet needs were observed by age, ethnicity, hospital type, education level, and ownership of health insurance (p>0.05).
Conclusions
A high burden of unmet needs were observed among women with mBC in this middle-income Asian setting with limited supportive care services. In resource-limited settings, routine assessment of unmet needs as well as presence of dedicated personnel to navigate access to supportive services may play a key role in alleviating these needs.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
University Malaya.
Funding
Novartis Corporation (M) Sdn Bhd.
Disclosure
N. Bhoo-Pathy: Financial Interests, Personal and Institutional, Research Funding: Novartis, Zuellig Pharma; Financial Interests, Personal, Other, Honorarium: Novartis, Pfizer, Roche; Non-Financial Interests, Personal and Institutional, Other, Research equipment: Roche Diagnostics. M. Thiagarajan: Non-Financial Interests, Personal and Institutional, Advisory Role: Jannsen, Astellas, MSD, Pfizer, Novartis; Financial Interests, Personal and Institutional, Research Funding: Novartis, MSD, Jannsen, Roche. N.F. Bt Abdul Satar: Financial Interests, Personal, Other, Honoraria: Roche, MSD Malaysia, Eisai, Ipsen Pharma; Financial Interests, Personal, Other, Honorarium: Pfizer, Zuellig Pharma; Financial Interests, Personal and Institutional, Research Funding, PI Clinical Trial: MSD Malaysia, Naluri Sdn Bhd, Viracta Therapeutics, KURA Oncology; Non-Financial Interests, Personal, Project Lead: Cancer ECHO UM. M. Md Yusof: Financial Interests, Institutional, Advisory Board, disease and treatment indications advisory board or expert committee meeting, as panellist or chair or speaker: AstraZeneca, Specialsed Therapeutics, Roche, MSD, Pfizer, Novartis, Eli Lily, Eisai; Financial Interests, Institutional, Invited Speaker, disease and treatment indications -speaker: Amgen; Financial Interests, Institutional, Invited Speaker, invited speaker for local conferences: Zuellig Pharma; Financial Interests, Institutional, Invited Speaker, speaker: Mundi Pharma, GSK; Financial Interests, Institutional, Other, speaker for doctors only platform webinar: Docquity; Financial Interests, Personal, Advisory Board, advisory board member for amivantamab in exon 20 insertion tve cancer: Johnson and Johnson; Financial Interests, Personal, Ownership Interest, surgery and oncology centre small partnership: Integrated Oncology Centre ( Kuala Lumpur) Sdn Bhd; Financial Interests, Personal and Institutional, Local PI, KEYNOTE 119, KEYNOTE 355, KEYNOTE B49, KEYNOTE4280A, KEYNOTE 076: MSD; Financial Interests, Personal and Institutional, Funding, local funding for multicentre data collection and reporting: Mundi Pharma; Financial Interests, Personal and Institutional, Local PI, Compleement1, EPIKB3, CANOPY-A: Novartis; Financial Interests, Personal and Institutional, Local PI, CAPITELLO, L-MOCA, ADAURA-A, SERENA-4: AstraZeneca; Financial Interests, Personal and Institutional, Local PI, GLOW study: Astellas; Financial Interests, Personal and Institutional, Local PI, ARc -10 study: ARCUS 10; Non-Financial Interests, Personal, Leadership Role, secretary: Malaysian Oncological Society; Non-Financial Interests, Personal, Advisory Role, clinician advisor: Breast Cancer women association ( NGO), KANWORK ( NGO); Non-Financial Interests, Personal, Advisory Role, government led group to evaluate the cost effectiveness of neoadjuvant anti HER2 therapy: Health Technology Assessment Trastuzumab in neoadjuvant treatment early breast cancer; Non-Financial Interests, Personal, Advisory Role, Clinical Practice Guideline for Breast Cancer 2020-2021: Ministry of Health Malaysia; Non-Financial Interests, Personal, Advisory Role, Specialty Education Subcommittee: Malaysian Medical Council Malaysia; Non-Financial Interests, Personal, Principal Investigator, PALOMA-3 trial: Johnson and Johnson. R. Kaur: Financial Interests, Personal, Other, Honoraria for consultancy and advisory role: Roche, Pfizer, Novartis, AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
239P - Elevated baseline C-reactive protein is a prognostic indicator for OS in patients with metastatic non clear cell renal cell carcinoma treated with systemic therapy
Presenter: Ryuichi Mizuno
Session: Poster Display
Resources:
Abstract
240P - Efficacy and safety of first-line combination therapy with ipilimumab + nivolumab for metastatic renal cell carcinoma in a single institution in Japan
Presenter: Naoya Nagaya
Session: Poster Display
Resources:
Abstract
241P - First-line cabozantinib in metastatic renal cell carcinoma (mRCC): A real-world exploratory study from eastern India
Presenter: Tamojit Chaudhuri
Session: Poster Display
Resources:
Abstract
244P - Clinicopathologic feature and treatment outcome of metastatic non clear cell kidney cancer: A single centre experience from India
Presenter: Somnath Roy
Session: Poster Display
Resources:
Abstract
245P - The role of TGF-β in the formation of the protumor phenotype of circulating neutrophils at different stages of renal cancer
Presenter: Ilseya Myagdieva
Session: Poster Display
Resources:
Abstract
246P - Impact of renal impairment on first-line treatment in metastatic urothelial cancer
Presenter: Stephanie Wakeling
Session: Poster Display
Resources:
Abstract
247P - Adjuvant chemoradiotherapy in the management of bladder adenocarcinoma compared to multiple treatment modalities
Presenter: Othman Mohammed
Session: Poster Display
Resources:
Abstract
248P - Screening zinc homeostasis-related genes identifies metallothionein 1H (MT1H) as a potential prognostic biomarker in clear cell renal cell carcinoma (ccRCC)
Presenter: Eyad Al Masoud
Session: Poster Display
Resources:
Abstract
249P - The prognostic utility of Progestogen associated Endometrial protein (PAEP) gene expression in clear cell renal cell carcinoma (ccRCC)
Presenter: Leen Lataifeh
Session: Poster Display
Resources:
Abstract
250P - Impact of adjuvant chemo(radio)therapy in stage I/II testicular seminoma
Presenter: Mahmoud Eleisawy
Session: Poster Display
Resources:
Abstract